Evidence map›Paper›PMID 36550787›Full record

ArticleMolecular oncology2024

YB-1 regulates mesothelioma cell migration via snail but not EGFR, MMP1, EPHA5 or PARK2.

Karin Schelch, Sebastian Eder, Benjamin Zitta, Monica Phimmachanh, Thomas G Johnson, Dominik Emminger, Andrea Wenninger-Weinzierl, Caterina Sturtzel, Hugo Poplimont, Alexander Ries and 7 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Karin SchelchCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Sebastian EderCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Benjamin ZittaCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Monica PhimmachanhCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Thomas G JohnsonCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Dominik EmmingerCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Andrea Wenninger-WeinzierlSt. Anna Children's Cancer Research Institute, Innovative Cancer Models, Vienna, Austria.
Caterina SturtzelSt. Anna Children's Cancer Research Institute, Innovative Cancer Models, Vienna, Austria.
Hugo PoplimontSt. Anna Children's Cancer Research Institute, Innovative Cancer Models, Vienna, Austria.
Alexander RiesCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Konrad HoetzeneckerDepartment of Thoracic Surgery, Medical University of Vienna, Austria.
Mir A HodaDepartment of Thoracic Surgery, Medical University of Vienna, Austria.
Walter BergerCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.
Martin DistelSt. Anna Children's Cancer Research Institute, Innovative Cancer Models, Vienna, Austria.
Balazs DomeDepartment of Thoracic Surgery, Medical University of Vienna, Austria.
Glen ReidDepartment of Pathology, Dunedin School of Medicine, New Zealand.
Michael GruschCenter for Cancer Research and Comprehensive Cancer Center, Medical University of Vienna, Austria.ORCID 0000-0001-5486-9340
Comprehensive Cancer Center Vienna · ATCancer Research Institute of the Slovak Academy of Sciences · SKMedical University of Vienna · ATDunedin Public Hospital · NZSemmelweis University · HUThe University of Sydney · AUUniversity of Technology Sydney · AU

Funding

Austrian Science Fund FWF I 3977Austrian Science Fund FWF T 1062
6 · The paper itself

Abstract

Pleural mesothelioma (PM) is characterized by rapid growth, local invasion, and limited therapeutic options. The multifunctional oncoprotein Y-box-binding protein-1 (YB-1) is frequently overexpressed in cancer and its inhibition reduces aggressive behavior in multiple tumor types. Here, we investigated the effects of YB-1 on target gene regulation and PM cell behavior. Whereas siRNA-mediated YB-1 knockdown reduced cell motility, YB-1 overexpression resulted in scattering, increased migration, and intravasation in vitro. Furthermore, YB-1 stimulated PM cell spreading in zebrafish. Combined knockdown and inducible overexpression of YB-1 allowed bidirectional control and rescue of cell migration, the pattern of which was closely followed by the mRNA and protein levels of EGFR and the protein level of snail, whereas the mRNA levels of MMP1, EPHA5, and PARK2 showed partial regulation by YB-1. Finally, we identified snail as a critical regulator of YB-1-mediated cell motility in PM. This study provides insights into the mechanism underlying the aggressive nature of PM and highlights the important role of YB-1 in this cancer. In this context, we found that YB-1 closely regulates EGFR and snail, and, moreover, that YB-1-induced cell migration depends on snail.

Indexed as

MesotheliomaMesothelioma, MalignantPleural NeoplasmsAnimalsCell Line, TumorCell MovementErbB ReceptorsGene Expression Regulation, NeoplasticMatrix Metalloproteinase 1RNA, MessengerZebrafishErbB ReceptorsMatrix Metalloproteinase 1RNA, Messengercell migrationEGFRpleural mesotheliomasnailYB‐1

Identifiers

PMID36550787
PMCPMC10994239
OpenAlexW4312114826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.